Lupin Ltd Share Price
(LUPIN)
₹2067.1
as on 04:01PM, 29 Apr 2025
Lupin Performance
Day's Low
Day's High
₹2,053.2Day's Price Range₹2,115.952 Week's Low
52 Week's High
₹1,493.352-Week Price Range₹2,402.9
| Returns % | |
| 1 Month Return | + 5.71 % |
| 3 Month Return | + 0.13 % |
| 1 Year Return | + 25.59 % |
| Market Stats | |
| Previous Close | ₹2,105.40 |
| Open | ₹2,107.70 |
| Volume | 11.23L |
| Upper Circuit | ₹2,315.90 |
| Lower Circuit | ₹1,894.90 |
| Market Cap | ₹94,376.56Cr |
Lupin Fundamentals
P/E Ratio
32.85
PEG Ratio
1.39
Market Cap
₹94,376.56 Cr
P/B Ratio
3.58
EPS
42.47
Dividend Yield
0.49
Sector
Pharmaceuticals
ROE
11.92
Mutual Fund Holdings of Lupin
Lupin Analyst Rating
based on 36 analysts
58.33%
Buy
30.56%
Hold
11.11%
Sell
Based on 36 analysts offering long term price targets for Lupin. An average target of ₹2272.5
Source: S&P Global Market Intelligence
Lupin Share analysis
Lupin price forecast by 36 analysts
Upside of9.94%
High
₹2626
Target
₹2272.50
Low
₹1900
Lupin target price ₹2272.5, a slight upside of 9.94% compared to current price of ₹2067.1. According to 36 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Lupin revenue growth forecast
Expected growth rate Q1, FY2027:34.76%
Forecast
Actual
Including amortisation and stock based compensations
Lupin EPS growth forecast
EPS estimate Q1, FY2027:111.57%
Forecast
Actual
Source: S&P Global Market Intelligence
Key events for Lupin Ltd
Lupin Reduces Price of Key TB Drug by 25% - 25 Apr, 2025
Lupin Limited has successfully reduced the price of the tuberculosis drug pretomanid by 25%, making it available for $169 per treatment course through the Global Drug Facility. This price cut enhances global access to essential TB medicine.Lupin Secures USFDA Approval for Tolvaptan Tablets - 24 Apr, 2025
Lupin Ltd has received USFDA approval for its generic Tolvaptan tablets, granting it 180 days of exclusivity. This marks a significant entry into the nephrology market, with estimated annual sales of $1.47 billion. The product will be manufactured at Lupin's Nagpur facility and is expected to launch soon, enhancing Lupin's market position and revenue potential.Lupin's Strategic Moves and Market Developments - 23 Apr, 2025
Lupin Ltd is making significant strides with the launch of gTolvaptan in the US, gaining market sentiment, while facing challenges from patent rulings and product recalls. The company also enhances its cloud infrastructure and receives NABL accreditation for diagnostics labs.Lupin Pharmaceuticals Recalls Antidepressant Medication - 22 Apr, 2025
Lupin Pharmaceuticals Inc, a subsidiary of Lupin Ltd, is recalling 2,724 bottles of clomiPRAMINE hydrochloride capsules due to failed impurity specifications, marking a Class II recall initiated on April 18.Lupin Faces Patent Challenges but Maintains Growth - 17 Apr, 2025
Lupin Ltd faces a patent ruling in favor of Astellas Pharma regarding Myrbetriq, with a trial set for 2026. Despite this, Lupin's financials remain strong, with a significant profit increase and positive ratings from brokerages. The company received regulatory approval for its Nagpur facility, indicating ongoing operational compliance.Lupin Faces Setback in Myrbetriq Patent Case - 16 Apr, 2025
Lupin Ltd shares dropped significantly after a US court ruled against them in a patent case involving Myrbetriq, blocking their market access and potentially leading to financial penalties. The ruling is expected to impact future revenue forecasts negatively.Lupin Receives Positive USFDA Inspection Report - 10 Apr, 2025
Lupin Ltd announced the closure of all outstanding USFDA inspections at its Aurangabad facility with the receipt of an establishment inspection report. Despite a broader drop in pharma stocks due to tariff concerns, analysts remain optimistic about Lupin's market position.Lupin Digital Health Expands Patient Base Significantly - 08 Apr, 2025
Lupin Digital Health has doubled its patient base to 10,000 and aims for 50,000 by year-end. The platform focuses on cardiac rehabilitation and prevention, leveraging partnerships and innovative digital solutions.Lupin Reports Strong Q3 FY25 Earnings Growth - 06 Apr, 2025
Lupin's Q3 FY25 earnings show a 10.6% YoY revenue increase to Rs 5,618.6 crore and a 38.81% rise in net profit to Rs 858.86 crore. The company maintains strong U.S. sales and received multiple FDA approvals, despite facing competitive pressures and currency fluctuations. Promoter stake remains stable at 45.41%, indicating confidence in growth.Lupin Expands UK Presence with Renascience Acquisition - 02 Apr, 2025
Lupin Limited has acquired UK-based Renascience Pharma for £12.3 million, strengthening its portfolio in specialty pharmaceuticals and expanding its market presence in the UK.Lupin Board Approves Key Business Transfers - 31 Mar, 2025
Lupin Ltd's board has approved the transfer of its API R&D division to a wholly owned subsidiary and modified the OTC business transfer to LUPINLIFE Consumer Healthcare Ltd.Concerns Over US Tariffs Impacting Indian Pharma - 30 Mar, 2025
The Indian pharma sector, including Lupin Ltd, faces challenges due to a 10% tariff on US pharma imports, raising concerns among industry groups about cost burdens on distributors and generic manufacturers.
Insights on Lupin Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRevenue Rich
Revenue is up for the last 4 quarters, 4.99K Cr → 5.82K Cr (in ₹), with an average increase of 4.9% per quarter
- POSITIVE IMPACT
Best in 3 Years
In the last 3 years, LUPIN has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
MF Holding Up
Mutual Funds have increased holdings from 16.92% to 17.55% in Mar 2025 quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 4 quarters, 359.43 Cr → 855.16 Cr (in ₹), with an average increase of 20.5% per quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, LUPIN stock has moved up by 2.9%
NO EFFECTAgainst Peers
In the last 1 year, Divis Laboratories Ltd has given 51.1% return, outperforming this stock by 22.5%
NEGATIVE IMPACTPromoter Holding Down
Promoters have decreased holdings from 46.95% to 46.92% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 22.04% to 21.46% in Mar 2025 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 6.26% to 6.20% in Mar 2025 quarter
Lupin Financials
Lupin Index Inclusions
Lupin Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 46.92% | 0.00 | |
| Foreign Institutions | 21.46% | 0.00 | |
| Mutual Funds | 17.55% | 0.00 | |
| Retail Investors | 6.2% | 0.00 | |
| Others | 7.87% | 0.00 |
Lupin Key Indicators
Lupin Valuation
Lupin in the last 5 years
Lowest (-6437.86x)
December 3, 2018
Today (32.85x)
April 29, 2025
Industry (54.77x)
April 29, 2025
Highest (517.33x)
December 2, 2022
Lupin Earnings and Dividends
Lupin Ltd Earnings Results
Lupin Ltd’s net profit jumped 39.48% since last year same period to ₹855.16Cr in the Q3 2024-2025. On a quarterly growth basis, Lupin Ltd has generated 0.3% jump in its net profits since last 3-months.
Read More about Earnings ResultsLupin Ltd Dividends May,2024
In the quarter ending March 2024, Lupin Ltd has declared dividend of ₹8 - translating a dividend yield of 0.58%.
Read More about Dividends
Lupin Technicals Summary
Bearish
Neutral
Bullish
Lupin Ltd is currently in a Bullish trading position according to technical analysis indicators.
Lupin Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹94,376.56 Cr | 29.49% | 0.51 | ₹1,935 Cr | ₹20,010 Cr | |
| BUY | ₹13,895.15 Cr | -4.49% | 0.52 | ₹413 Cr | ₹2,013 Cr | |
| BUY | ₹70,875.13 Cr | 18.65% | 0.56 | ₹3,168 Cr | ₹29,001 Cr | |
| HOLD | ₹89,358.61 Cr | 34.83% | 0.64 | ₹3,854 Cr | ₹19,547 Cr | |
| BUY | ₹63,962.50 Cr | 13.95% | 0.53 | NA | NA |
About Lupin
The company's top products include a wide range of prescription and over-the-counter drugs, including antibiotics, cardiovascular medications, antidiabetics, and anti-asthmatics. Lupin Ltd also manufactures and markets a variety of branded products, including Metoject, Lupitac, and Lupizole. In addition, the company produces a number of popular generic drugs, such as Amlodipine, Montelukast, and Cetirizine.
Lupin Ltd is one of the world's leading manufacturers of APIs, with a portfolio that includes more than 200 APIs and intermediates. The company also produces a range of animal health products, such as veterinary vaccines, feed supplements, and pet care products.
Revenue: ₹5,618.56Cr as on December 2024 (Q4 24)
Net Profit: ₹858.86Cr as on December 2024 (Q4 24)
Listing date: 30 Nov, 1994
Chairperson Name: M D Gupta
| Organisation | Lupin |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
FAQs on Lupin Ltd
What is Lupin Ltd price today?
Lupin Ltd share price today stands at ₹2067.1, Open: ₹2107.7, Previous Close: ₹2105.4, High: ₹2115.9, Low: ₹2053.2, 52 Week High: ₹2402.9, 52 Week Low: ₹1493.3.
How to Buy Lupin Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Lupin Ltd shares
What are today's traded volumes of Lupin Ltd?
Today's traded volume of Lupin Ltd(LUPIN) is 11.23L.
What is today's market capitalisation of Lupin Ltd?
Today's market capitalisation of Lupin Ltd(LUPIN) is ₹94376.56Cr.
What is the 52 Week High and Low Range of Lupin Ltd?
How much percentage Lupin Ltd is down from its 52 Week High?
Lupin Ltd (LUPIN) share price is ₹2067.1. It is down -13.97% from its 52 Week High price of ₹2402.9
How much percentage Lupin Ltd is up from its 52 Week low?
Lupin Ltd (LUPIN) share price is ₹2067.1. It is up 38.42% from its 52 Week Low price of ₹1493.3